Healthcare / Drug Manufacturers - Specialty & GenericNasdaqCM
$2.36
-0.21 (-8.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $4.2M · quality 48.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$304M
P/E
15.7x
↓EV/EBITDA
3.6x
↓ROE
8.5%
↑Gross Margin
75.6%
↑Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2015–2025 · 10 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-4.3%
FCF / Net income
-0.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $563.0M · net income $37.0M · FCF $-24.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | $563.0M | $563.0M | $482.0M | $433.1M | $450.9M | $467.4M | $338.3M | $261.0M | $193.4M | $0.00 | $0.00 | — |
| Net Income | $37.0M | $37.0M | $861000.00 | $4.9M | $15.5M | $94.2M | $17.2M | $-38.7M | $-64.8M | $-8.4M | $-17.0M | — |
| EBITDA | $82.8M | $82.8M | $24.1M | $36.0M | $40.3M | — | — | — | — | — | — | — |
| EPS | 0.15 | 0.15 | -0.01 | 0.04 | 0.12 | 0.70 | 0.15 | -0.42 | -0.94 | — | — | — |
| Gross Margin | 75.6% | 75.6% | 76.0% | 75.4% | 76.7% | 75.6% | 74.2% | 70.9% | 64.4% | — | — | — |
| Operating Margin | 9.9% | 9.9% | 4.5% | 2.9% | 4.9% | 15.5% | 7.9% | -11.4% | -26.7% | — | — | — |
| Net Margin | 6.6% | 6.6% | 0.2% | 1.1% | 3.4% | 20.2% | 5.1% | -14.8% | -33.5% | — | — | — |
| Balance Sheet | ||||||||||||
| Debt/Equity | 0.19 | 0.19 | 0.11 | 0.43 | 0.47 | 0.31 | 0.49 | 0.95 | — | -3.40 | — | — |
| Current Ratio | 3.53 | 3.53 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||
| Free Cash Flow | $-24.5M | $-24.5M | $4.2M | $6.6M | $-9.0M | $30.8M | $-12.2M | $-39.5M | $-62.5M | $-5.9M | $-6.2M | — |
| Returns | ||||||||||||
| ROE | 8.5% | 8.5% | 0.2% | 1.8% | 5.8% | 39.0% | 12.2% | -74.4% | -162.3% | 54.8% | 106.3% | — |
| Valuation | ||||||||||||
| P/E | 15.73 | 15.73 | — | 105.25 | 22.00 | — | — | — | — | — | — | — |
| EV/EBITDA | 3.57 | 3.57 | 13.10 | 15.94 | 9.20 | — | — | — | — | — | — | — |
| P/B | 0.71 | 0.71 | 1.06 | 2.01 | 1.32 | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||
| Revenue Growth | 16.8% | 16.8% | 11.3% | -3.9% | — | 38.2% | 29.6% | 34.9% | — | — | — | — |
| EPS Growth | 1600.0% | 1600.0% | -125.0% | -66.7% | — | 366.7% | 135.7% | 55.3% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
11.8%
EPS terminal req.
$0.21
Spread vs growth
1588.2%
5Y implied EPS CAGR
11.1%
EPS terminal req.
$0.25
Spread vs growth
1588.9%
10Y implied EPS CAGR
10.5%
EPS terminal req.
$0.41
Spread vs growth
1589.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → 0.15
Residual
-13.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.